It was specifically developed for the dietary management of type 2 diabetes and has a proof-of-concept randomized controlled trial supporting its A1C and glucose-lowering claims
Adverse events with gastrointestinal symptoms were observed in 37.1%43.6% of patients in the tirzepatide group and 20.4% of patients in the placebo cohort
Here is what that looks like practically
Typical 12-month results include 10 to 15% body weight loss (20 to 35 pounds for a 200-pound person), 2 to 4 inch waist circumference reduction, noticeable improvement in body composition especially with exercise, and significant improvement in metabolic markers if they were elevated
The net cardiovascular risk picture for most retatrutide patients is therefore: lower blood pressure, improved lipid profile, reduced systemic inflammation (lower hsCRP) alongside a modest heart rate elevation
You may not be a fit if youre pregnant, trying to become pregnant, breastfeeding, have certain gastrointestinal conditions, have a history of specific endocrine cancers, or have other medical factors that make GLP-1 treatment inappropriate
